Conventional antidepressant medications, which act on monoaminergic systems, display significant limitations, including a time lag of weeks to months and low rates of therapeutic efficacy. GLYX-13 is a novel glutamatergic compound that acts as an N-methyl-Daspartate (NMDA) modulator with glycine-like partial agonist properties; like the NMDA receptor antagonist ketamine GLYX-13 produces rapid antidepressant actions in depressed patients and in preclinical rodent models. However, the mechanisms underlying the antidepressant actions of GLYX-13 have not been characterized. Here we use a combination of neutralizing antibody (nAb), mutant mouse and pharmacological approaches to test the role of brain-derived neurotrophic factor-tropomyosin-related kinase B (BDNF-TrkB) signaling in the actions of GLYX-13. The results demonstrate that the antidepressant effects of GLYX-13 are blocked by intra-medial prefrontal cortex (intra-mPFC) infusion of an anti-BDNF nAb or in mice with a knock-in of the BDNF Val66Met allele, which blocks the processing and activity-dependent release of BDNF. We also demonstrate that pharmacological inhibitors of BDNF-TrkB signaling or of L-type voltage-dependent Ca 2+ channels (VDCCs) block the antidepressant behavioral actions of GLYX-13. Finally, we examined the role of the Rho GTPase proteins by injecting a selective inhibitor into the mPFC and found that activation of Rac1 but not RhoA is involved in the antidepressant effects of GLYX-13. Together, these findings indicate that enhanced release of BDNF through exocytosis caused by activation of VDCCs and subsequent TrkB-Rac1 signaling is required for the rapid and sustained antidepressant effects of GLYX-13.
INTRODUCTION
Major depressive disorder (MDD) is a chronic, debilitating illness that affects~17% of the population and is one of the leading causes of disability among all medical illnesses. 1 Currently, MDD is treated with monoaminergic agents, but large-scale clinical trials (that is, STAR*D) show that these drugs can take weeks to months to produce a therapeutic response, have limited efficacy and low rates of remission. [2] [3] [4] On the other hand, there is growing evidence that the glutamatergic system has an important role in the pathophysiology and treatment of MDD. [5] [6] [7] Importantly, clinical findings demonstrate that glutamatergic agents, notably ketamine, a dissociative anesthetic that blocks N-methyl-Daspartate (NMDA) receptor channel activity, causes rapid (within hours) and long-lasting (7-10 days) antidepressant effects. 8, 9 However, use of ketamine is associated with cognitive impairment and psychotomimetic symptoms, [10] [11] [12] stimulating studies to develop alternative glutamatergic approaches for the treatment of MDD.
One such agent is GLYX-13 (also known as Rapastinel), a novel allosteric modulator of the NMDA receptor with glycine-like partial agonist properties. 13, 14 Recent clinical results show that GLYX-13 rapidly decreases depressive symptoms within hours and these effects are sustained for up to 7 days. 15 Importantly, GLYX-13 does not produce the dissociative and psychotomimetic side effects caused by ketamine. Rodent studies report that GLYX-13 injection also produces rapid antidepressant effects that last for at least 1 week, and increases synaptic number and function in the medial prefrontal cortex (mPFC). 16, 17 These findings indicate that GLYX-13, like ketamine rapidly stimulates neuroplasticity signaling that results in long-lasting structural alterations that underlie the antidepressant behavioral responses. 17 The structural as well as behavioral actions of ketamine result in part from increased brain-derived neurotrophic factor (BDNF) signaling. [18] [19] [20] The antidepressant actions of ketamine are blocked in BDNF deletion mutant mice, as well as in mice with a knock-in of the BDNF Met allele, a functional polymorphism found in humans that blocks the processing and activity-dependent release of BDNF. 18, 19, 21 Studies in primary neuronal cultures provide direct evidence that ketamine increases BDNF release in an activitydependent manner that also requires L-type voltage-dependent calcium channel (VDCC) activation. 20 Together, these findings indicate that the actions of ketamine require rapid, activitydependent release of BDNF.
Despite this progress on ketamine, the molecular mechanisms underlying the antidepressant actions of GLYX-13, notably the role of BDNF signaling have not been determined. The current study addresses this question using a combination of approaches, including an anti-BDNF neutralizing antibody (nAb), BDNF Val66Met knock-in mice and pharmacological inhibitors of BDNF-tropomyosin-related kinase B (TrkB) receptor signaling and VDCCs. In addition, we examine the role of downstream BDNFTrkB pathways involved in synapse formation, namely activation of Rho GTPase signaling that controls BDNF-dependent synaptic plasticity during structural long-term potentiation. 22 
MATERIAL AND METHODS

Animals and drug administration
Male Sprague-Dawley rats, C57BL/6 J mice or mutant BDNF Val66Met knock-in mice were used. GLYX-13 were dissolved in saline and injected through tail vein. Verapamil was injected 30 min before injection of GLYX-13. Animal use and procedures were in accordance with the National Institutes of Health guidelines and approved by the Yale University Animal Care and Use Committees.
Surgical and infusion procedures
Guide cannula were implanted into mPFC bilaterally. A function-blocking anti-BDNF antibody, K252a, NSC23766, Y-27632 or BDNF were infused bilaterally.
Behavior studies
The forced swim test (FST), novelty suppressed feeding test (NSFT) and female urine-sniffing test (FUST) was carried out as previously described for rat and mouse. [23] [24] [25] In FST, each animal was placed in the swim cylinders for a 10 min period and videotaped. Data were analyzed by scoring the immobility time. In NSFT, animals were food-deprived overnight and placed in an open field with a small amount of food in the center. The latency to feed was measured. In FUST, each animal was exposed to a cotton-tipped applicator infused with water or fresh urine from females of the same strain for 5 min and the time spent sniffing the cotton-tipped applicator was measured.
Primary cortical culture and BDNF analysis
Primary cortical culture and measurement of BDNF was performed as previously described. 20 Cortical neuron dissected from E18 embryos were treated 3 nM GLYX-13 and the effects of anti-BDNF antibody on mTOR signaling and verapamil on BDNF release were examined using western blot and enzyme-linked immunosorbent assay.
Western blot
The phosphorylation level of mTOR, Erk, TrkB and p21-activated kinase (PAK), and expression of postsynaptic proteins were evaluated in western blot following previous report. 23 Total levels of the respective protein or GAPDH (Cell Signaling, Danvers, MA, USA; #5174, 1:1000) were used for loading control.
Immunohistochemistry
Rats were perfused transcardially. Brains were cut in a cryostat for coronal section. The number of c-Fos-positive cells was counted in the regions near the injection sites in the mPFC from two sections per animal after 3-3′-diaminobenzidine staining.
Statistics
Data for TrkB and pTrkB western blots and dose response experiments were analyzed using one-way analysis of variance (ANOVA). Data for FUST were analyzed using repeated-measure three-way ANOVA with time spent sniffing water or urine as a repeated measure. According to the interaction of three factors (drug, microinjection/genotype and water/urine), post hoc analysis using two-way ANOVA followed by Tukey's multiple comparison test or paired t-test were performed. Data for NSFT were analyzed using Kaplan-Meier survival analysis followed by the Mantel-Cox log-rank test. When a main effect was observed, treatment effect was analyzed using the Bonfferoni multiple comparison test. For other experiments, normality was analyzed with the D'Agostino-Pearson test. Depending on the experiment, the results were analyzed using two-way ANOVA followed by Tukey's or Duncan's multiple comparison test or Kruskal-Wallis test followed by Dunn's multiple comparison test.
RESULTS
Antidepressant actions of GLYX-13 are blocked by anti-BDNF antibody infusion into mPFC Previous studies demonstrate that infusion of GLYX-13 into the mPFC is sufficient to produce rapid antidepressant responses similar to systemic GLYX-13 administration, providing the rationale for targeting mPFC. 26 Rats were infused with a BDNF nAb (0.5 μg per side) 30 min before GLYX-13 (3 mg kg − 1 intravenous (i.v.)) injection and behavioral testing started 24 h later (Figure 1a) . In vehicle-infused rats, GLYX-13 produced a significant antidepressant effect in the FST (day 1, Figure 1c ) and NSFT (day 4, Figure 1e ), but no effect on locomotor activity or home cage feeding (Figures 1f and g ). In the FUST, a measure of motivation and reward in males, GLYX-13 administration produced a significant increase in time sniffing female urine, but not water (day 3, Figure 1d ). Infusion of the BDNF nAb before GLYX-13 injection significantly blocked the behavioral action of GLYX-13 in these three tests of antidepressant activity; BDNF nAb alone had no effect on these three behaviors or on locomotor activity or home cage feeding (Figures 1c-g ). We also show that GLYX-13 increases c-Fos immunolabeling, a marker of neuronal activity, in infralimbic PFC, replicating a previous report, 17 and infusion of the BDNF nAb, but not control IgG, blocks the induction of Fos+ Figure 1 . Intra-medial prefrontal cortex (mPFC) infusion of brain-derived neurotrophic factor (BDNF) neutralizing antibody (nAb) blocks the antidepressant effects of GLYX-13 in rats. (a) Rats were implanted with bilateral cannula in the mPFC and allowed to recover for~2 weeks. The anti-BDNF nAb (0.5 μg per side) was infused into the mPFC 30 min before administration of vehicle or GLYX-13 (3 mg kg − 1 , intravenous (i.v.)). Twenty-four hours after GLYX-13 administration behavioral studies were initiated and conducted over the next 4 days (c-g , i.v.) or ketamine (10 mg kg − 1 , i.p.) and PFC dissections were collected 1 h later. Levels of phosphorylated tropomyosin-related kinase B (TrkB) (l) and total TrkB receptor (m) in crude synaptosomal preparations were determined by western blot analysis. Levels of GAPDH were determined to control for protein levels and results are the ratio of each protein divided by GAPDH. (n) The ratio of pTrkB/TrkB is also calculated. The results are shown as mean ± s.e.m. n = 5 per group. *P o0.05 compared with the control group (two-tailed unpaired Student's t-test).
neurons (Figures 1j and k) . To determine whether BDNF is required for the sustained antidepressant effects of GLYX-13, we tested the effects of BDNF nAb infusion 24 h after GLYX-13 administration. The results demonstrate that infusion of BDNF nAb into the mPFC at this time point had no effect on the antidepressant effects of GLYX-13 in the FST or NSFT (Supplementary Figures 1a-e) .
BDNF binds as a dimer to the TrkB tyrosine kinase receptor, resulting in autophosphorylation and activation of downstream pathways. 27 To evaluate the effect of GLYX-13 on the activity of TrkB, we analyzed levels of the phosphorylated and activated form of the TrkB receptor by western blot analysis. We compared the effects of GLYX-13 (3 mg kg − 1 , i.v.) with ketamine (10 mg kg − 1 , intraperitoneal (i.p.)), each with a separate vehicle (i.v. or i.p.) and mPFC was dissected 1 h after drug administration. A single dose of GLYX-13 rapidly and significantly increased levels of phospho-TrkB without effecting total TrkB demonstrating enhanced BDNF-TrkB signaling (Figures 1l-n) . This induction of phospho-TrkB was not observed 24 h later, indicating that the effect was transient (Supplementary Figures 1f-h ) and consistent with the finding that the infusion of BDNF nAb at this time point had no effect on behavior (Supplementary Figure 1) .
Antidepressant effects of GLYX-13 are blocked in BDNF Val66Met knock-in mice We have reported that the antidepressant actions of ketamine are blocked in BDNF Met knock-in mice, 18 a human polymorphism that blocks the processing and activity-dependent release of mature BDNF. 28 Here the behavioral actions of GLYX-13 in BDNF Val66Met knock-in mice were evaluated. In studies to determine the effective dose of GLYX-13 in mice we found that 1 and 3 mg kg − 1 (tail vein, i.v.) were effective in both the FST and NSFT (Supplementary Figures 2b and e) ; however, 3 mg kg − 1 of GLYX-13 resulted in a small but significant increase in locomotor activity 48 h after dosing (Supplementary Figure 2c) . The 1 mg kg − 1 dose had no effect on locomotor activity at either 24 or 48 h after dosing, so this dose was used for further studies ( Supplementary Figures 2c and d) Wild-type Val/Val littermates and BDNF Val/Met and Met/Met knock-in mice were tested (Figure 2a ). There were no differences in baseline levels of immobility in the FST (Figure 2b ), but Met/Met mice showed reduced water-sniffing time in the FUST and increased latency to feed in NSFT compared to Val/Val mice (Figures 2c and d) suggesting increased anxiety in Met/Met, consistent with previous results. 28 In wild-type mice, we observed significant antidepressant effects of GLYX-13 in all of three tests for antidepressant activity with no effects on locomotor activity or home cage feeding (Figures 2b-f) . In Val/Met mice, GLYX-13 produced a significant effect in the FST, but no significant effects in the FUST or NSFT (Figures 2b-d) . In Met/Met mice, there were no significant effects of GLYX-13 in FST, FUST or NSFT (Figures 2b-d) . These findings indicate that the behavioral actions of GLYX-13 require processing and activity-dependent release of mature BDNF.
Previous studies demonstrate that GLYX-13 increases synaptic number and function, including increased levels of synaptic proteins in the mPFC. 17 Here we found that in vehicle-treated mice, basal levels of PSD95 and synapsin1 were significantly decreased in Met/Met mice compared to Val/Val mice (Figures 2g  and h ). Administration of GLYX-13 increased levels of PSD95, synapsin1 and GluR1 in wild-type mice, but these effects were blocked in Val/Met and Met/Met mice (Figures 2g-i) . The results indicate that processing and release of mature BDNF is required for the synaptic actions of GLYX-13.
Behavioral actions of GLYX-13 are blocked by inhibition of L-type VDCC Our previous studies have demonstrated that the antidepressant behavioral actions of ketamine are blocked by pre-treatment with a selective L-type VDCC antagonist (that is, verapamil or nifedipine). 19 This is consistent with evidence that depolarizationinduced release of BDNF in cultured neurons requires activation of VDCC. 29 Here we tested the effects of verapamil (10 mg kg − 1 i.p.) on the behavioral effects of GLYX-13 in rats (3 mg kg −1 i.v.; Figure 3a ). This dose of verapamil was chosen based on pharmacokinetic studies demonstrating effective blood and brain concentrations. 30 GLYX-13 produced significant antidepressant responses in the FST, NSFT and FUST, and these effects were completely blocked by pre-treatment with verapamil (Figures 3c-g ). Verapamil administration alone had no effect on any of the antidepressant behaviors, or on locomotor activity or home cage feeding (Figures 3c-g ).
To test the effects of verapamil on GLYX-13-induced BDNF-TrkB signaling, we analyzed levels of phospho-TrkB. A single dose of GLYX-13 (3 mg kg − 1 , i.v.) increased levels of phospho-TrkB 1 h after drug administration, and this effect was completely blocked by pre-treatment of verapamil (Figures 3h-j ). These findings demonstrate that VDCC activation is essential to GLYX-13 enhancement of BDNF-TrkB signaling. To directly examine the influence of GLYX-13 on BDNF release and effects of verapamil, we utilized primary neuronal cultures. The results demonstrate that incubation of primary neuronal cultures with GLYX-13 (3 nM) increases BDNF release into the culture media (Figure 3k ), similar to a previous report; 20 in addition, preincubation with verapamil (10 μM) completely blocked the GLYX-13-induction of BDNF release (Figure 3k; Supplementary Figure 3) . Blockade of GLYX-13 induction of BDNF release was also observed at lower concentrations of verapamil (0.1 μM, Supplementary Figure 3) .
Antidepressant effects of GLYX-13 are blocked by inhibition of BDNF-TrkB signaling To directly test the requirement for TrkB activation we determined the effects of pre-treatment with a selective TrkB receptor antagonist (K252a) on the antidepressant actions of GLYX-13. Rats were infused with K252a (25 pmol per side) into the mPFC 30 min before administration of GLYX-13 (3 mg kg − 1 i.v.), and were tested 24 h later (Figure 4a ). In vehicle-infused rats, GLYX-13 produced significant antidepressant effects in the FST, FUST and NSFT, and these responses were blocked by K252a infusion (Figures 4c-g ). K252a microinjection alone had no effect on behavior compared to vehicle (Figures 4c-g ).
We also tested the role of BDNF-TrkB in the signaling actions of GLYX-13 in primary cortical cultured neurons. GLYX-13 increases phosphorylated levels of mTOR and ERK, and these effects were blocked by pre-treatment of anti-BDNF antibody ( Supplementary  Figures 4a and b) . Together the results demonstrate a requirement for BDNF-TrkB receptor activation in the signaling, as well as behavioral actions of GLYX-13.
Rho GTPase is required for the antidepressant behavioral actions of GLYX-13 Recent evidence demonstrates that Rho GTPases Rac1 and RhoA mediate BDNF-dependent synaptic structural plasticity. 22 To determine whether the antidepressant effects of GLYX-13 require activation of Rho GTPase signaling, mice were infused with selective inhibitors of Rac1 (NSC23766; 3.76 nmol per side) or ROCK (Rho-associated protein kinase), a major downstream signaling kinase of RhoA (Y-27632; 8 nmol per side, bilateral) into mPFC just after GLYX-13 (1 mg kg − 1 , i.v.); behavioral analysis was conducted starting 24 h later (Figure 5a; Supplementary  Figure 5a) . The dose and timing of Rho GTPase inhibitor infusions , effect of GLYX-13 × effect of genotype × water/urine: F 1,1 = 3.20, P o0.05; two-way ANOVA, effect of GLYX-13 × effect of genotype: F 2,58 = 3.24, P o0.05; effect of GLYX-13: F 1,58 = 2.54, P40.05; effect of genotype: F 2,58 = 9.94, P o0.01); and (d) the novelty suppressed feeding test (NSFT; Mantel-Cox log-rank test: χ 2 = 79.45, P o0.0001). No significant effects were seen in (e) locomotor activity (interaction: F 2,58 = 0.138, P40.05; effect of GLYX-13: F 1,58 = 0.356, P40.05; effect of genotype: F 2,58 = 0.733, P40.05) or (f) home cage feeding (interaction: F 2,58 = 3.37, P o0.05; effect of GLYX-13: are based on previous reports. [31] [32] [33] In vehicle (saline)-infused mice, GLYX-13 produced a significant antidepressant effect in the FST, FUST and NSFT (Figures 5b-d; Supplementary Figures 5b-d) . Moreover, the Rac1 selective inhibitor NSC23766 significantly blocked the behavioral action of GLYX-13 in FST, FUST and NSFT (Figures 5b-d) , but alone had no effects on any behaviors tested.
In contrast, infusions of Y-27632 failed to block the effects of GLYX-13 in these three tests for antidepressant activity (Supplementary Figures 5b-d) .
To directly test the requirement for Rho GTPase signaling in the antidepressant actions of BDNF, the influence of the Rac1 and ROCK inhibitors on BDNF-mediated behavior in the FST were determined (Figures 5a; Supplementary Figure 5a) . We used the same animals used for the GLYX-13 studies, and counterbalanced the groups so that half of the vehicle-treated animals were included in the second vehicle infusion group and the other half for the BDNF infusion group, and half of the GLYX-13-treated animals for vehicle infusion group and the other half for the BDNF infusion group (Supplementary Table 1 ). We confirmed there was no significant difference between the immobility of the vehicleinfused group and that of BDNF-infused group in the first FST (Supplementary Figure 6) . BDNF infusion into the mPFC resulted in significant antidepressant effects in the FST, as previously reported in hippocampus; 34 moreover, infusion of the Rac1 inhibitor NSC23766 but not Y-27632 completely blocked the antidepressant response to BDNF (Figure 5g; Supplementary Figure 5g) .
We also examined downstream effectors of Rac1 by measuring the phosphorylation levels of PAK. For these studies we examined synaptosomal fractions of PFC from BDNF Val66Met knock-in mice to avoid difficulties with microdissections that would be required for analysis of samples from the inhibitor infusion studies. GLYX-13 administration increased phospho-PAK levels in wild-type Val/Val, but not in Val/Met or Met/Met mice (Figure 5i ). These data indicate that Rac1-PAK signaling is stimulated by GLYX-13 and that this is mediated by BDNF-TrkB signaling.
DISCUSSION
The results demonstrate that the antidepressant actions of GLYX-13 are mediated by neuronal activation of VDCCs, activitydependent release of BDNF and stimulation of TrkB signaling, notably new evidence for activation of Rac1 (Supplementary Figure 7) . These findings are consistent with recent studies demonstrating that structural plasticity of spine synapse formation requires BDNF release and activation of TrkB-Rho GTPase signaling. 22, 35 Importantly, the results indicate that BDNF is ). (b) Diagram showing postsynaptic signaling. Significant effects of GLYX-13 were observed and were blocked by K252a in (c) the forced swim test (FST; interaction: F 1,32 = 5.49, P o0.05; effect of GLYX-13: F 1,32 = 2.97, P40.05; effect of K252a: F 1,32 = 0.0899, P40.05); (d) the female urinesniffing test (FUST; three-way analysis of variance (ANOVA), effect of GLYX-13 × effect of K252a × water/urine: F 1,1 = 13.19, P o0.05; two-way ANOVA, effect of GLYX-13 × effect of K252a: F 1,32 = 12.41, P o0.01; effect of GLYX-13: F 1,32 = 4.98, P o0.05; effect of K252a: F 1,32 = 2.90, P40.05); and (e) the novelty suppressed feeding test (NSFT; Mantel-Cox log-rank test: χ 2 = 22.16, P o0.0001). No significant effects were seen in (f) locomotor activity (interaction: F 1,32 = 0.954, P40.05; effect of GLYX-13: F 1,32 = 1.06, P40.05; effect of K252a: F 1,32 = 0.323, P40.05) or (g) home cage feeding (interaction: F 1,32 = 1.11, P40.05; effect of GLYX-13: F 1,32 = 0.647, P40.05; effect of K252a: F 1,32 = 1.46, P40.05). The results are shown as mean ± s.e.m. n = 9 per group. *P o0.05 and **P o0.01 Tukey's, Dunn's or Bonfferoni's multiple comparison test, following significant results of two-way ANOVA, Kruskal-Wallis or Mantel-Cox log-rank test. (h) Location of cannula placements in the mPFC. Figure 5 . Intra-medial prefrontal cortex (mPFC) infusion of Rac1 antagonist blocks the antidepressant effects of GLYX-13 in mice. (a) Mice were implanted with bilateral cannula in the mPFC and allowed to recover for~2 weeks. NSC23766 (3.76 nmol per side) was infused into the mPFC just after administration of vehicle or GLYX-13 (1 mg kg − 1 , intravenous). Twenty-four hours after GLYX-13 administration behavioral studies were initiated and conducted over the next 4 days (b-f). Significant effects of GLYX-13 were observed and were blocked by NSC23766 in (b) the forced swim test (FST; interaction: F 1,33 = 5.91, P o0.05; effect of GLYX-13: F 1,33 = 2.09, P40.05; effect of NSC23766: F 1,33 = 3.62, P40.05); (c) the female urine-sniffing test (FUST; three-way analysis of variance (ANOVA), effect of GLYX-13 × effect of NSC23766 × water/urine: F 1,1 = 5.68, Po0.05; two-way ANOVA, effect of GLYX-13 × effect of NSC23766: F 1,33 = 6.12, P o0.05; effect of GLYX-13: packaged and released from postsynaptic spines and acts in an autocrine cell autonomous manner to enhance spine maturation and number. 35 This work extends recent studies demonstrating that GLYX-13 increases mTORC1 signaling in the mPFC and increases spine synapse number and function 17 ( Supplementary  Figure 7) . Together the results demonstrate that GLYX-13 causes activity-dependent BDNF release that produces rapid and sustained synaptic and behavioral responses in rodent models of antidepressant response. It will be important in future studies to determine whether the rapid actions of GLYX-13 in more valid rodent models, such as chronic unpredictable stress 36 also require activity-dependent BDNF release.
Previous studies have demonstrated that the actions of ketamine are blocked by infusion of an anti-BDNF nAb into the mPFC and in BDNF deletion mutant mice. 19, 21 Infusion of GLYX-13 into the mPFC is reported to produce an antidepressant response, 26 demonstrating that mPFC is a critical target for the actions of GLYX-13.
37, 38 Here we show that infusion of a functionblocking anti-BDNF Ab into the mPFC also blocks the antidepressant behavioral actions of GLYX-13 in three different paradigms, including a model of behavioral despair (FST), motivation/reward (FUST) and anxiety (NSFT). Together these studies indicate that antidepressant actions of GLYX-13, like ketamine, require extracellular BDNF that is increased as a result of activity-dependent release.
To further test this hypothesis we conducted studies using mice with a knock-in of the BDNF Met allele, which blocks activitydependent processing and release of BDNF, but does not influence transcript levels. 28 BDNF Met/Met mice showed anxiety-like behaviors in the FUST and NSFT models, consistent with a previous report. 28 Importantly, the results show that the antidepressant actions of GLYX-13 are completely blocked in Met/ Met mice, and partially blocked in Val/Met mice in all three tests for antidepressant activity. These findings provide further evidence that activity-dependent release of BDNF is required for the actions of GLYX-13, although it is possible that the anxiety phenotype contributes to this blockade. These results may be clinically important as the Met polymorphism is found in~25% of Caucasians, 39, 40 and the antidepressant response to ketamine is significantly reduced in BDNF Met patients, most of which were heterozygous Met carriers by~50% compared to Val/Val patients. 41 The results of the current study suggest that BDNF Met carriers would also show a reduced response to GLYX-13, a possibility that will be tested in future clinical studies AMPA receptor-stimulated, activity-dependent release of BDNF in cultured neurons is reported to require activation of VDCC, and the subsequent increase in intracellular Ca 2+ . 29 We have reported that the antidepressant actions of ketamine are blocked by pretreatment with an AMPA receptor antagonist, or with a selective inhibitor of VDCCs. 19, 23 The actions of GLYX-13 are blocked by pretreatment with an AMPA receptor antagonist, indicating a requirement for neuronal activity. 26 In the current study we demonstrate that the antidepressant effects of GLYX-13 are also blocked by pre-treatment with the L-type VDCC antagonist verapamil. Together these studies indicate that stimulation of AMPA receptors and VDCCs are required for the antidepressant actions of GLYX-13 via the release of BDNF. This possibility was directly tested in primary cultured neurons, demonstrating that GLYX-13-stimulated release of BDNF is blocked by incubation with low concentrations of verapamil. However, given the actions of verapamil on blood pressure we cannot rule out the possibility that peripheral physiological effects could contribute to the interference with the behavioral actions of GLYX-13.
A recent study has demonstrated that structural synaptic plasticity is mediated by activity-dependent release of BDNF and subsequent autocrine stimulation of TrkB signaling. 35 In the current study the results show that GLYX-13, as well as ketamine increase phospho-TrkB levels in the mPFC, consistent with evidence of increased BDNF release and activity. A role for TrkB signaling is directly supported by results showing that infusion of a selective TrkB inhibitor into the mPFC blocked the antidepressant behavioral actions of GLYX-13. BDNF-TrkB stimulation regulates multiple downstream pathways, including mTORC1, which is increased by GLYX-13. 17 In the current study we also tested the role of Rho GTPases, which are critical regulators of the actin cytoskeleton and neuronal morphogenesis, including spine synapse plasticity. 42 Activation of Rho GTPases, notably Rac1 and RhoA contribute to BDNF-dependent synaptic plasticity. 22 , 35 Here we demonstrate that an inhibitor of Rac1, but not RhoA-ROCK signaling blocks the antidepressant effects for GLYX-13, as well as the effects of direct infusions of BDNF into the mPFC. The results also show that GLYX-13 increases levels of phospho-PAK, a key downstream kinase of Rac1, and this effect is blocked in BDNF Met/Met mice. The results are consistent with previous studies demonstrating a role for Rac1 in BDNF-dependent synaptic plasticity, 22, 43 while the actions of RhoA in synapse formation have been mixed. 22, [43] [44] [45] Together, the results demonstrate that activation of Rac1 signaling is essential for antidepressant effects of GLYX-13 and BDNF by enhancing actin polymerization, 22, 42 and are consistent with our recent report that GLYX-13 increases spine head diameter, number and function in mPFC pyramidal neurons. 17 Together the results demonstrate that the antidepressant actions of GLYX-13 occur via activity-dependent stimulation of Ltype VDCC and release of BDNF. Extracellular BDNF then acts in an autocrine manner to activate TrkB signaling, including Rac1, as well as mTORC1 signaling as reported in our recent study 17 (Supplementary Figure 7) . These findings extend previous work, indicating that the ability of GLYX-13 to increase spine number, maturation and function is mediated not only by activation of mTORC1 signaling and formation of synaptic proteins (that is, PSD95 and GluA1) but also by activation of Rac1 and enhancement of actin polymerization (Supplementary Figure 7) . It is possible that Rac1 is also activated by Ca 2+ -CaMKII signaling that occurs via stimulation of NMDA receptors, 22 but blockade of Rac1-PAK1 signaling in BDNF Met mice indicates that this effect occurs primarily via BDNF-TrkB signaling (Supplementary Figure 7) . The findings presented here raise the possibility that other rapid acting antidepressants, notably ketamine, also increases spine number and function, in part via stimulation of Rac1.
The current GLYX-13 findings together with previous work on ketamine demonstrate a common signaling pathway underlying the effects of these two rapid acting antidepressant: AMPA and L-type VDCC activity-dependent BDNF release and stimulation of TrkB-mTORC1 downstream signaling [17] [18] [19] [20] [21] (Supplementary Figure 7) ; whether ketamine also requires Rac1 signaling is currently being tested. These convergent actions are surprising as GLYX-13 is a glycine site partial agonist and ketamine is an NMDA channel blocker. However, the convergence of these two agents could be explained by different initial cellular targets: GLYX-13 could act directly on postsynaptic NMDA receptors on pyramidal neurons to directly increase Ca 2+ signaling and ketamine could block NMDA receptors on tonic firing GABA interneurons to cause a glutamate burst. Studies are currently being conducted to test this hypothesis by cell-specific knockdown of NMDA receptor subunits on GABA vs glutamate neurons in the PFC.
Despite these convergent actions, GLYX-13 lacks the side-effect profile of ketamine. This could be related to the cell-specific actions of these two agents and the difference in glutamate transmission; ketamine causes a rapid, transient burst of glutamate (30-60 min) 46 that coincides temporally with the dissociative and psychotomimetic effects in humans and the locomotor and sensory motor gating deficits in rodents. 9, 26, 47 Preliminary studies demonstrate that GLYX-13 does not cause an increase in extracellular glutamate in the PFC and this could account for the lack of ketamine-like side effects. 48 Further studies of the initial cellular targets of GLYX-13 and ketamine as well as characterization of the signaling pathways underlying the antidepressant vs side effects are needed to address these questions.
CONFLICT OF INTEREST
The authors declare no conflict of interest.
